Ceapro Inc. (OTCMKTS:CRPOF) is a Canada‐based life sciences company specializing in the development, production and commercialization of natural bioactive ingredients. The company’s portfolio targets multiple end markets, including nutraceuticals, functional foods, medical devices, cosmetics and pharmaceuticals. Ceapro leverages proprietary extraction and fermentation technologies to create high‐purity compounds that address key health and wellness trends.
Among its core offerings are L-glutamine and glutamine dipeptide, which support muscle recovery and gut health, and barley‐derived beta-glucans, known for their immune-modulating properties. Ceapro also produces specialty peptides and mushroom extracts designed for use in skincare formulations, dietary supplements and medical nutrition products. These ingredients are formulated to meet rigorous quality standards, including compliance with Good Manufacturing Practices (GMP).
Headquartered in Saskatoon, Saskatchewan, Ceapro operates two manufacturing facilities in the province: a biotechnology plant for fermentation-based processes and a barley fractionation site for cereal‐based ingredients. The company’s products are distributed to customers across North America, Europe and the Asia-Pacific region, with strategic partnerships in key markets to support formulation, regulatory approvals and marketing efforts.
Founded in 1991 as a spin-off from McGill University, Ceapro has grown under the leadership of President and Chief Executive Officer Terry Kelly and a board of directors with extensive experience in biotechnology, finance and commercial development. The management team continues to advance research collaborations and expand the company’s commercial footprint, positioning Ceapro to capitalize on growing global demand for natural, science-based health and wellness solutions.
AI Generated. May Contain Errors.
